Published • loading... • Updated
Axsome: Q3 Earnings Snapshot – WTOP News
Philips said higher sales and improved margins helped offset recall costs as its Respironics unit reached a settlement agreement in principle with U.S. authorities.
- On Monday, November 2, 2026, Axsome Therapeutics reported $260 million in third-quarter revenue, representing a 52% year-over-year increase, while simultaneously narrowing its net loss to $12.9 million for the period.
- Management activated 8,200 new AUVELITY prescribers during the quarter, bringing the total to 77,000 unique providers. This growth was driven by rapid adoption within the primary care sector, which has become a key market.
- With AUVELITY prescriptions reaching 302,000 during the third quarter, the company also achieved broad market penetration as payer coverage expanded to roughly 89% of total lives, substantiating the drug's continued commercial success.
- Axsome ended the quarter with a $313.9 million cash balance. Management states this liquidity is sufficient to fund anticipated operations until the company reaches its goal of sustained cash flow positivity.
- The FDA's target action date for the AXS-12 cataplexy treatment is set for May 1, 2027. This milestone represents a critical development for the company's expanding sleep franchise beyond current commercial offerings.
Insights by Ground AI
109 Articles
109 Articles
Coverage Details
Total News Sources109
Leaning Left20Leaning Right13Center28Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 33%
C 46%
R 21%
Factuality
To view factuality data please Upgrade to Premium
